Denali Therapeutics Stock Current Valuation
| DNLI Stock | USD 14.43 0.18 1.23% |
Valuation analysis of Denali Therapeutics helps investors to measure Denali Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The Denali Therapeutics' current Enterprise Value Over EBITDA is estimated to increase to -6.28. The Denali Therapeutics' current Enterprise Value Multiple is estimated to increase to -6.28. Fundamental drivers impacting Denali Therapeutics' valuation include:
Fairly Valued
Today
Please note that Denali Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Denali Therapeutics is based on 3 months time horizon. Increasing Denali Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Denali Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Denali Stock. However, Denali Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.43 | Real 14.04 | Target 39.73 | Hype 14.43 | Naive 15.12 |
The intrinsic value of Denali Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Denali Therapeutics' stock price.
Estimating the potential upside or downside of Denali Therapeutics helps investors to forecast how Denali stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Denali Therapeutics more accurately as focusing exclusively on Denali Therapeutics' fundamentals will not take into account other important factors: Denali Therapeutics Company Current Valuation Analysis
Denali Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Denali Therapeutics Current Valuation | 1.31 B |
Most of Denali Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Denali Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Denali Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Denali Therapeutics is extremely important. It helps to project a fair market value of Denali Stock properly, considering its historical fundamentals such as Current Valuation. Since Denali Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Denali Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Denali Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Denali Current Valuation Historical Pattern
Today, most investors in Denali Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Denali Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Denali Therapeutics current valuation as a starting point in their analysis.
Denali Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Denali Therapeutics has a Current Valuation of 1.31 B. This is 90.87% lower than that of the Biotechnology sector and 71.76% lower than that of the Health Care industry. The current valuation for all United States stocks is 92.11% higher than that of the company.
Denali Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Denali Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics of similar companies.Denali Therapeutics is currently under evaluation in current valuation category among its peers.
Denali Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Denali Therapeutics from analyzing Denali Therapeutics' financial statements. These drivers represent accounts that assess Denali Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Denali Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.7B | 9.1B | 3.5B | 2.9B | 3.4B | 2.3B | |
| Enterprise Value | 1.7B | 8.7B | 3.3B | 2.9B | 3.2B | 2.2B |
Denali Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Denali Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Denali Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Denali Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 1.31 B | ||||
| Shares Outstanding | 145.22 M | ||||
| Shares Owned By Insiders | 9.57 % | ||||
| Shares Owned By Institutions | 90.99 % | ||||
| Number Of Shares Shorted | 8.69 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 1.70 X | ||||
| Price To Sales | 3,644 X | ||||
| Gross Profit | (396.44 M) | ||||
| EBITDA | (487.34 M) | ||||
| Net Income | (422.77 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 42.29 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 8.53 X | ||||
| Cash Flow From Operations | (347.69 M) | ||||
| Short Ratio | 10.01 X | ||||
| Earnings Per Share | (2.57) X | ||||
| Target Price | 36.63 | ||||
| Number Of Employees | 422 | ||||
| Beta | 1.46 | ||||
| Market Capitalization | 2.1 B | ||||
| Total Asset | 1.37 B | ||||
| Retained Earnings | (1.54 B) | ||||
| Working Capital | 762.23 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
| Net Asset | 1.37 B |
About Denali Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Denali Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out Denali Therapeutics Piotroski F Score and Denali Therapeutics Altman Z Score analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.